Two key metrics are required to determine optimal therapy for fluid overload:
No clinical viable options for accurate measurement of intravascular volume exist in current practice.
The frontline treatment for Congestive Heart Failure is fluid removal using diuretic therapies. It is difficult to determine the appropriate dose leading to too much or too little fluid removal.
The challenge – to correctly dose diuretics to manage a patient’s volume status and kidney function when you cannot accurately and readily measure these parameters.
- Costanzo, MR et al.1
- American Heart Association
>1 Million patients are hospitalized from HF in the US annually
ADHF accounts for approximately 60% of total HF expenditures
90% of HF admissions due to volume overload, yet there is not a current clinically viable way to measure volume.
“The FAST BioMedical solution has the potential to address the clinical challenge of heart failure in real time. Having volume and renal measurements at the bedside makes the FAST BioMedical technology promising and unique.”
“The technology this company is developing to guide timely, accurate care to heart failure patients promises to meaningfully improve both the clinical outcome and the economic impact of heart failure.”
“The FAST technology is easy to use and can be comfortably translated to routine hospital protocols. This new technology has the potential to allow physicians to detect early kidney function loss and renal reserve, thus enabling earlier therapeutic interventions. In short, it opens the door to exciting new endeavors in the world of Nephrology.”
1Costanzo, MR et al. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. JACC 2007;40:675-683
